Abstract
Aim This pilot study reports on the uptake of I-123-interleukin 2 (IL-2) in metastatic renal cell carcinoma (MRCC) patients and its relationship to prognostic factors of response or failure of MRCC to cytokines treatment.
Methods. Nine consecutive patients with MRCC underwent an I-123-IL-2 scan (6 male and 3 female; mean age 64 years; range 51-78). Uptake in metastases was related to a summed score of 4 independent factors, predictive of rapid progression under cytokine treatment as defined by Negrier et al.
Results. Four patients presented with metastases at one site, 4 at 2 sites and one patient at 3 different sites. Summed scores were: 5 patients had a summed score of 1; 3 a summed score of 2 and I patient a summed score of 3. Uptake of I-123-IL-2 by tumor tissue was found in only 2 patients. Uptake occurred in I patient with a summed score of 3 and in 1 with a summed score of 2.
Conclusion In this small series of patients with MRCC, I-123-IL-2 uptake was found in tumors of 2 patients who less likely will benefit from cytokine treatment. Additional studies are needed to assess the relationship between the pretreatment uptake of I-123-IL2 in MRCC and the response to IL-2 therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 352-356 |
| Number of pages | 5 |
| Journal | Quarterly Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 51 |
| Issue number | 4 |
| Publication status | Published - Dec-2007 |
| Event | 18th International Congress of the International-Research-Group-in-Immuno-Scintigraphy-and-Therapy (IRIST) - Duration: 1-Jul-2006 → … |
Keywords
- carcinoma
- renal cell
- interleukins
- scintigraphy
- radiolabelling
- RENAL-CELL CARCINOMA
- GAMMA-CHAIN
- CYTOPLASMIC DOMAINS
- BETA-CHAIN
- INTERLEUKIN-2-RECEPTOR